Verteporfin photodynamic therapy in the age of antiangiogenic therapy

Authors: Barbazetto, Irene A; Takahashi, Beatriz S

Source: Expert Review of Ophthalmology, Volume 3, Number 4, August 2008 , pp. 365-383(19)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Photodynamic therapy with verteporfin was the first approved pharmacological treatment for choroidal neovascularization in patients with age-related macular degeneration, pathologic myopia and ocular histoplasmosis syndrome. With the introduction of anti-VEGF therapy, verteporfin photodynamic therapy is no longer the first line of treatment for neovascular age-related macular degeneration. Ongoing clinical trials will determine the future role of PDT alone or as part of a more individualized combination therapy.

Keywords: choroidal neovascularization; combination therapy; intraocular anti-VEGF therapy; macular degeneration; photodynamic therapy; verteporfin

Document Type: Research article

DOI: http://dx.doi.org/10.1586/17469899.3.4.365

Affiliations: 1: VRM Consultants of New York, 460 Park Avenue, 5th Floor, New York, NY 10022, USA., Email: ib206@columbia.edu

Publication date: 2008-08-01

More about this publication?

Expert Review of Ophthalmology provides an important platform for commentary and debate on current and emerging approaches in ocular medicine.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites